Marta López‐Yurda

3.2k citations

61 papers · 833 indexed · h-index 18

Otorhinolaryngology top 2%
- Head and Neck Cancer Studies 9
Oncology top 10%
- Cancer Immunotherapy and Biomarkers 9
- Cancer Treatment and Pharmacology 7
- Ear and Head Tumors 6
- HER2/EGFR in Cancer Research 5
- Cutaneous Melanoma Detection and Management 5
Pathology and Forensic Medicine top 10%
Pulmonary and Respiratory Medicine top 10%
- Renal cell carcinoma treatment 6
Reproductive Medicine top 10%
Molecular Biology
- Melanoma and MAPK Pathways 6

Co-authors: C. Rasch Alfons J. M. Balm Maarten Lindeboom Gérard J. van den Berg Frank Hoebers Wilma D. Heemsbergen Margot Tesselaar Harm van Tinteren
Cited by: Otorhinolaryngology Oncology Pathology and Forensic Medicine
Journals: Nature Medicine (1 paper)Journal of Clinical Oncology (8 papers)SHILAP Revista de lepidopterología (1 paper)
Partner nations: Netherlands United Kingdom Spain

In The Last Decade

Marta López‐Yurda

56 papers receiving 821 citations

Peers

Countries citing papers authored by Marta López‐Yurda

Since Specialization

Citations

This map shows the geographic impact of Marta López‐Yurda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta López‐Yurda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta López‐Yurda more than expected).

Fields of papers citing papers by Marta López‐Yurda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta López‐Yurda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta López‐Yurda. The network helps show where Marta López‐Yurda may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Marta López‐Yurda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marta López‐Yurda Line = papers co-authored together Marta López‐Yurda links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	LBA95 Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: The randomized phase II NESCIO trial Annals of Oncology ·F. Burgers,A. de Ruijter,N.M. Graafland,Maurits van Montfoort,Marta López‐Yurda,Pieter van Hagen,Patricia Zondervan,Sybren P. Rynja,Marit J. Yska,An F.C. Ruiter,Astrid M. van Leeuwen,R. de Vries,Brunolf W. Lagerveld,Daniël J. Vis,S. Wilgenhof,H.V. van Thienen,C.U. Blank,Koen van der Mijn,A. Bex,J.B.A.G. Haanen	2025	0
2	LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma Annals of Oncology ·M.W. Lucas,A.M. Menzies,P. Dimitriadis,S C M A Wijnen,Marta López‐Yurda,Richard A. Scolyer,B. van de Wiel,Robyn P.M. Saw,A. Kuijpers,A. Torres Acosta,Joyce Sanders,M.S. Carlino,Jan Willem de Groot,E. Kapiteijn,K. Suijkerbuijk,P. Rutkowski,Shahneen Sandhu,Astrid A.M. van der Veldt,G.V. Long,C.U. Blank	2025	0
3	LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial Annals of Oncology ·M.W. Lucas,A.M. Menzies,Marta López‐Yurda,Richard A. Scolyer,B. van de Wiel,R.P.M. Saw,W. Van Houdt,Nigel G. Maher,A. Torres Acosta,M. Boers-Sonderen,G. Hospers,M.S. Carlino,Jan Willem de Groot,E. Kapiteijn,K. Suijkerbuijk,P. Rutkowski,Shahneen Sandhu,Astrid A.M. van der Veldt,G.V. Long,C.U. Blank	2024	6
4	Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. Journal of Clinical Oncology ·Christian U. Blank,Minke W. Lucas,Richard A. Scolyer,Bart A. van de Wiel,Alexander M. Menzies,Marta López‐Yurda,Alexander Christopher Jonathan Van Akkooi,Winan J. van Houdt,Robyn P.M. Saw,Alex Torres Acosta,Serigne Lo,Geke A.P. Hospers,Matteo S. Carlino,Jan Willem de Groot,Ellen Kapiteijn,Karijn P.M. Suijkerbuijk,Piotr Rutkowski,Shahneen Sandhu,Astrid Aplonia Maria Van Der Veldt,Georgina V. Long	2024	9
5	Staging peritoneal metastases in colorectal cancer: The correlation between MRI, surgical and histopathological peritoneal cancer index European Journal of Surgical Oncology ·C.J.V. Rijsemus,N.F.M. Kok,A. Aalbers,Remond J.A. Fijneman,Marta López‐Yurda,Doenja M. J. Lambregts,R.G.H. Beets-Tan,Pétur Snæbjörnsson,Max J. Lahaye	2024	0
6	Botulinum Toxin Type A (BoNT-A) Use for Post-Stroke Spasticity: A Multicenter Study Using Natural Language Processing and Machine Learning Toxins ·M.J. Antón Andrés,M. I. Molina,José Gabriel Pérez,Santiago Pina,Noemí Tapiador,B. de la Calle,Mónica Martínez,Paula Ortega,María Belén Ruspaggiari,Consuelo Tudela,Marta Conejo,Pedro Leno,Marta López‐Yurda,Carmen Marhuenda,Carlos Arias-Cabrales,Pascal Maisonobe,Alberto Herrera,Ernesto Candau	2024	1
7	The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. Journal of Clinical Oncology ·Irene L. M. Reijers,Alexander M. Menzies,Judith M. Versluis,Robyn P.M. Saw,Winan J. van Houdt,Ellen Kapiteijn,Astrid Aplonia Maria Van Der Veldt,Karijn P.M. Suijkerbuijk,Hanna Eriksson,Geke A.P. Hospers,W. Martin C. Klop,Marta López‐Yurda,Lindsay G. Grijpink-Ongering,Maria Gonzalez,Andrew J. Spillane,Richard A. Scolyer,Bart A. van de Wiel,Alexander Christopher Jonathan Van Akkooi,Georgina V. Long,Christian U. Blank	2023	6
8	A Nomogram to Predict Severe Toxicity in DPYD Wild‐Type Patients Treated With Capecitabine‐Based Anticancer Regimens Clinical Pharmacology & Therapeutics ·Jonathan E. Knikman,Marta López‐Yurda,Didier Meulendijks,Maarten J. Deenen,Jan H.M. Schellens,Jos H. Beijnen,Annemieke Cats,Henk‐Jan Guchelaar	2023	4
9	First-line Systemic Treatment Strategies in Patients with Initially Unresectable Colorectal Liver Metastases: Phase III CAIRO5 Study of the Dutch Colorectal Cancer Group HPB ·Malcolm J. Bond,Karen Bolhuis,Geert Kazemier,Joost M. Klaase,Mike S.L. Liem,Arjen M. Rijken,C. Verhoef,Johannes H.W. de Wilt,Marta López‐Yurda,Cornelis J.A. Punt,Rutger‐Jan Swijnenburg	2023	1
10	Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial The Lancet Oncology ·S. Lot Aronson,Marta López‐Yurda,Simone N. Koole,Jules H. Schagen van Leeuwen,Hendrik W.R. Schreuder,Ralph H.M. Hermans,Ignace H. J. T. de Hingh,Mignon D J M van Gent,Henriëtte J.G. Arts,Maaike A. van der Aa,Peter A. van Dam,Peter Vuylsteke,Arend G. J. Aalbers,Victor J. Verwaal,Koen Van de Vijver,Neil K. Aaronson,Gabe S. Sonke,Willemien J. van Driel	2023	55
11	Abstract OT2-15-01: COntinue the SaMe systemic therapy after local ablative therapy for Oligoprogression in metastatic breast cancer - the COSMO study Cancer Research ·Cornelia AM Almekinders,Tessa G. Steenbruggen,Ingrid A.M. Mandjes,Marta López‐Yurda,Monique EMM Bos,T. Wiersma,Gabe S. Sonke	2023	0
12	1112P Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial Annals of Oncology ·Lianne Hoeijmakers,E.A. Rozeman,Marta López‐Yurda,Lindsay G. Grijpink-Ongering,Birthe C. Heeres,B. van de Wiel,Claudie C. Flohil,Ayşegül Sarı,Stijn W. T. P. J. Heijmink,Daan van den Broek,Annegien Broeks,Jan Willem de Groot,Marieke A. Vollebergh,Sofie Wilgenhof,H.V. van Thienen,John B.A.G. Haanen,Christian U. Blank	2023	1
13	Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer Gynecologic Oncology ·Ruby M. van Stein,Maurits P. Engbersen,Tessa H R Stolk,Marta López‐Yurda,Max J. Lahaye,Geerard L. Beets,Christianne Lok,Gabe S. Sonke,Willemien J. van Driel	2022	4
14	Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer Anouk K. M. Claessens,Frans Erdkamp,Marta López‐Yurda,Jeanette M. Bouma,Jeany M. Rademaker-Lakhai,A.H. Honkoop,H. deGraaf,Vivianne C. G. Tjan‐Heijnen,M.M.E.M. Bos	2020	1
15	Prophylactic fibrinogen concentrate administration in surgical correction of paediatric craniosynostosis European Journal of Anaesthesiology ·Andreas Machotta,Elise J. Huisman,Inge M. Appel,Saskia E. Luijnenburg,Marta López‐Yurda,Marjon H. Cnossen,C. Heleen van Ommen	2020	5
16	Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001 PLoS ONE ·Janna A. Hol,Marta López‐Yurda,Harm van Tinteren,Martine van Grotel,Jan Godziński,Gordan Vujanić,Foppe Oldenburger,Beatriz de Camargo,Gema Ramírez,Christophe Bergeron,Kathy Pritchard‐Jones,Norbert Graf,Marry M. van den Heuvel‐Eibrink	2019	28
17	Evaluation of boost irradiation in patients with intermediate‐risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP‐WT‐2001 Registry Pediatric Blood & Cancer ·Raquel Dávila Fajardo,Eva Oldenburger,Christian Rübe,Marta López‐Yurda,Kathy Pritchard‐Jones,Christophe Bergeron,Norbert Graf,Martine van Grotel,Harm van Tinteren,D.J. Saunders,Marry M. van den Heuvel‐Eibrink,Geert O. Janssens,Foppe Oldenburger	2018	8
18	Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG) Annals of Oncology ·Anouk K. M. Claessens,Monique E.M.M. Bos,SM de Groot,E van Leeuwen-Stok,Marta López‐Yurda,A.H. Honkoop,H. de Graaf,Edith van Druten,L. van Warmerdam,Maurice van der Sangen,Vivianne C. G. Tjan‐Heijnen,Frans Erdkamp	2017	1
19	Oral and oropharyngeal squamous cell carcinoma in young patients: The Netherlands Cancer Institute experience Head & Neck ·Hester S. van Monsjou,Marta López‐Yurda,Michael Hauptmann,Michiel W. M. van den Brekel,Alfons J. M. Balm,Volkert B. Wreesmann	2012	28
20	Reirradiation for Head-and-Neck Cancer: Delicate Balance Between Effectiveness and Toxicity International Journal of Radiation OncologyBiologyPhysics ·Frank Hoebers,Wilma D. Heemsbergen,S. Moor,Marta López‐Yurda,M. Klop,Margot Tesselaar,C. Rasch	2011	69

About Marta López‐Yurda

Marta López‐Yurda is a scholar working on Otorhinolaryngology, Oncology and Reproductive Medicine, having authored 61 papers that have together received 833 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Head and Neck Cancer Studies (9 papers), Cancer Treatment and Pharmacology (7 papers), Renal cell carcinoma treatment (6 papers), Ear and Head Tumors (6 papers), Melanoma and MAPK Pathways (6 papers), HER2/EGFR in Cancer Research (5 papers) and Cutaneous Melanoma Detection and Management (5 papers). The work is most often cited by research in Otorhinolaryngology (155 citations), Oncology (346 citations) and Pathology and Forensic Medicine (142 citations). Marta López‐Yurda has collaborated with scholars based in Netherlands, United Kingdom and Spain. Frequent co-authors include C. Rasch, Alfons J. M. Balm, Maarten Lindeboom, Gérard J. van den Berg, Frank Hoebers, Wilma D. Heemsbergen, Margot Tesselaar, Harm van Tinteren, I. Bing Tan and Michael Hauptmann. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact